Christoph Neuwirth

Deputy Head

Kantonsspital St. Gallen

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Christoph Neuwirth is the Deputy Head at Kantonsspital St. Gallen, Switzerland. His research focuses on neurological disorders, particularly spinal muscular atrophy and amyotrophic lateral sclerosis. Recent publications include studies on long-term treatment effects of nusinersen and the safety of various therapeutic agents in motor neuron diseases.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (7)

Dominique Neuhaus

University of Basel

SWITZERLAND

View details

Olivier Scheidegger

SWITZERLAND

View details

Cindy Shin-Yi Lin

Professor: The Kam Ling Barbara Lo Chair

University of Sydney

AUSTRALIA

View details

Robert Steinbach

Friedrich Schiller University Jena

GERMANY

View details

David Jacquier

Lausanne University Hospital

SWITZERLAND

View details

Georg M. Stettner

Head of Neuromuscular Center

University Children's Hospital Zurich

SWITZERLAND

View details

Veronika Kana

University Hospital of Zurich

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christoph Neuwirth

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Aseptic meningoencephalitis during nusinersen therapy in a patient with type III spinal muscular atrophy: a case report

Real-world data on the effect of long-term treatment with nusinersen over > 4 years in a cohort of Swiss patients with spinal muscular atrophy

Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.

Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind Crossover Trial.

Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy.

Chronic Pain in Patients with Spinal Muscular Atrophy in Switzerland: A Query to the Spinal Muscular Atrophy Registry

Neurophysiological and Imaging Biomarkers of lower motor neuron Dysfunction in Motor neuron diseases/Amyotrophic lateral sclerosis: IFCN Handbook Chapter

Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.

The Lateral Corticospinal Tract Sign: An MRI Marker for Amyotrophic Lateral Sclerosis.

Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Collaborators (7)

Dominique Neuhaus

Olivier Scheidegger

Cindy Shin-Yi Lin

Robert Steinbach

David Jacquier

Georg M. Stettner

Veronika Kana

Make your next move.

Christoph Neuwirth

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Aseptic meningoencephalitis during nusinersen therapy in a patient with type III spinal muscular atrophy: a case report

Real-world data on the effect of long-term treatment with nusinersen over > 4 years in a cohort of Swiss patients with spinal muscular atrophy

Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.

Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind Crossover Trial.

Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy.

Chronic Pain in Patients with Spinal Muscular Atrophy in Switzerland: A Query to the Spinal Muscular Atrophy Registry

Neurophysiological and Imaging Biomarkers of lower motor neuron Dysfunction in Motor neuron diseases/Amyotrophic lateral sclerosis: IFCN Handbook Chapter

Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.

The Lateral Corticospinal Tract Sign: An MRI Marker for Amyotrophic Lateral Sclerosis.

Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Collaborators (7)

Dominique Neuhaus

Olivier Scheidegger

Cindy Shin-Yi Lin

Robert Steinbach

David Jacquier

Georg M. Stettner

Veronika Kana

Make your next move.

Real-world data on the effect of long-term treatment with nusinersen over > 4 years in a cohort of Swiss patients with spinal muscular atrophy